CytRx Corporation  

(Public, NASDAQ:CYTR)   Watch this stock  
Find more results for CYTR
+0.121 (19.91%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.61 - 0.73
52 week 0.36 - 3.28
Open 0.61
Vol / Avg. 21.84M/9.68M
Mkt cap 133.10M
P/E     -
Div/yield     -
EPS -0.58
Shares 152.05M
Beta 1.16
Inst. own 11%
Jul 27, 2017
Q2 2017 CytRx Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 12, 2017
CytRx Corp Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
May 10, 2017
Q1 2017 CytRx Corp Earnings Release
Apr 19, 2017
CytRx Corp Conference Call to Discuss Outcome of FDA Regulatory Meeting
Mar 15, 2017
Q4 2016 CytRx Corp Earnings Release
Mar 14, 2017
CytRx Corp at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -25385.61%
Operating margin - -26128.81%
EBITD margin - -25860.50%
Return on average assets -76.60% -78.23%
Return on average equity -243.85% -155.40%
Employees 27 -
CDP Score - -


11726 San Vicente Blvd Ste 650
LOS ANGELES, CA 90049-5079
United States - Map
+1-310-8265648 (Phone)
+1-310-8266139 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Officers and directors

John Y Caloz Chief Financial Officer
Age: 63
Bio & Compensation  - Reuters
Daniel J. Levitt M.D., Ph.D. Chief Operating Officer, Chief Medical Officer
Age: 68
Bio & Compensation  - Reuters
Douglas Scott Wieland Ph.D. Senior Vice President - Drug Development
Age: 56
Bio & Compensation  - Reuters
David J. Haen Vice President - Business Development
Age: 37
Bio & Compensation  - Reuters
Olivia C. Ware Chief Commercial Officer
Bio & Compensation  - Reuters
Steven A. Kriegsman Chairman of the Board, President, Chief Executive Officer
Age: 73
Bio & Compensation  - Reuters
Earl W. Brien M.D. Director
Age: 56
Bio & Compensation  - Reuters
Louis J. Ignarro Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters